The global burden of liver disease: The major impact of China

Fu‐Sheng Wang, Jian‐Gao Fan, Zheng Zhang, Bin Gao, Hong‐Yang Wang – 28 August 2014 – Liver disease is a major cause of illness and death worldwide. In China alone, liver diseases, primarily viral hepatitis (predominantly hepatitis B virus [HBV]), nonalcoholic fatty liver disease, and alcoholic liver disease, affect approximately 300 million people.

The global burden of liver disease: The major impact of China

Fu‐Sheng Wang, Jian‐Gao Fan, Zheng Zhang, Bin Gao, Hong‐Yang Wang – 28 August 2014 – Liver disease is a major cause of illness and death worldwide. In China alone, liver diseases, primarily viral hepatitis (predominantly hepatitis B virus [HBV]), nonalcoholic fatty liver disease, and alcoholic liver disease, affect approximately 300 million people.

The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs

Margaret Hellard, David A Rolls, Rachel Sacks‐Davis, Garry Robins, Philippa Pattison, Peter Higgs, Campbell Aitken, Emma McBryde – 28 August 2014 – With the development of new highly efficacious direct‐acting antiviral (DAA) treatments for hepatitis C virus (HCV), the concept of treatment as prevention is gaining credence. To date, the majority of mathematical models assume perfect mixing, with injectors having equal contact with all other injectors. This article explores how using a networks‐based approach to treat people who inject drugs (PWID) with DAAs affects HCV prevalence.

Treatment of bile acid amidation defects with glycocholic acid

James E. Heubi, Kenneth D.R. Setchell, Pinky Jha, Donna Buckley, Wujuan Zhang, Philip Rosenthal, Carol Potter, Simon Horslen, David Suskind – 28 August 2014 – Bile acid amidation defects were predicted to present with fat/fat soluble vitamin malabsorption with minimal cholestasis. We identified and treated five patients (one male, four females) from four families with defective bile acid amidation due to a genetically confirmed deficiency in bile acid CoA:amino acid N‐acyl transferase (BAAT) with the conjugated bile acid, glycocholic acid (GCA).

FAK Is required for c‐Met/β‐catenin‐driven hepatocarcinogenesis

Na Shang, Maribel Arteaga, Ali Zaidi, Jimmy Stauffer, Scott J. Cotler, Nancy J. Zeleznik‐Le, Jiwang Zhang, Wei Qiu – 28 August 2014 – Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide and most patients with HCC have limited treatment options. Focal adhesion kinase (FAK) is overexpressed in many HCC specimens, offering a potential target for HCC treatment. However, the role of FAK in hepatocarcinogenesis remains elusive.

Subscribe to